BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 8627643)

  • 1. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer.
    Hansen RM; Ryan L; Anderson T; Krzywda B; Quebbeman E; Benson A; Haller DG; Tormey DC
    J Natl Cancer Inst; 1996 May; 88(10):668-74. PubMed ID: 8627643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line protracted venous infusion fluorouracil with CisDDP or carboplatin in advanced colorectal cancer.
    Garcia-Giralt E; Beuzeboc P; Deffontaines D; Diéras V; Dorval T; Jouve M; Palangie T; Scholl S; Pouillart P
    J Infus Chemother; 1996; 6(3):149-51. PubMed ID: 9229328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
    Hejna M; Kornek GV; Raderer M; Valencak J; Weinländer G; Fiebiger W; Miholic J; Scheithauer W
    Ann Oncol; 1998 Dec; 9(12):1309-14. PubMed ID: 9932161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH; Wils J; Lorenz M; Schöffski P; Voigtmann R; Bokemeyer C; Lutz M; Kleeberg C; Ridwelski K; Souchon R; El-Serafi M; Weiss U; Burkhard O; Rückle H; Lichnitser M; Langenbuch T; Scheithauer W; Baron B; Couvreur ML; Schmoll HJ;
    J Clin Oncol; 2003 Oct; 21(20):3721-8. PubMed ID: 12963704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.
    de Gramont A; Bosset JF; Milan C; Rougier P; Bouché O; Etienne PL; Morvan F; Louvet C; Guillot T; François E; Bedenne L
    J Clin Oncol; 1997 Feb; 15(2):808-15. PubMed ID: 9053508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study.
    Hartmann JT; Köhne CH; Schmoll HJ; Daikeler T; Kanz L; Bokemeyer C
    Oncology; 1998; 55(4):320-5. PubMed ID: 9663421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Guglielmi A; Aschele C; Grossi F; Tixi L; Sobrero A
    Cytotechnology; 1996; 19(3):215-9. PubMed ID: 8862009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
    O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
    J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study.
    Aranda E; Díaz-Rubio E; Cervantes A; Antón-Torres A; Carrato A; Massutí T; Tabernero JM; Sastre J; Trés A; Aparicio J; López-Vega JM; Barneto I; García-Conde J
    Ann Oncol; 1998 Jul; 9(7):727-31. PubMed ID: 9739438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.
    Sobrero A; Zaniboni A; Frassineti GL; Aschele C; Guglielmi A; Giuliani R; Ravaioli A; Lanfranco C; Caroti C; Arnoldi E; Barni S; Gallo L; Pessi MA; Turci D; Cortesi E; Grossi F; Frontini L; Piazza E; Bruzzi P; Labianca R
    Ann Oncol; 2000 Nov; 11(11):1413-20. PubMed ID: 11142481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged continuous infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer.
    Leichman CG; Leichman L; Spears CP; Rosen PJ; Jeffers S; Groshen S
    J Natl Cancer Inst; 1993 Jan; 85(1):41-4. PubMed ID: 8416255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
    Benson AB
    Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E; Cervantes A; Dorta J; Blanco E; Fernández-Martos C; Cruz-Hernandez JJ; Carrato A; Gonzalez-Mancha R; García-Conde J; Díaz-Rubio E
    Cancer; 1995 Aug; 76(4):559-63. PubMed ID: 8625147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer.
    Rougier P; Paillot B; LaPlanche A; Morvan F; Seitz JF; Rekacewicz C; Laplaige P; Jacob J; Grandjouan S; Tigaud JM; Fabri MC; Luboinski M; Ducreux M
    Eur J Cancer; 1997 Oct; 33(11):1789-93. PubMed ID: 9470834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial comparing weekly bolus 5-fluorouracil plus leucovorin versus monthly 5-day 5-fluorouracil plus leucovorin in metastatic colorectal cancer.
    Wang WS; Lin JK; Chiou TJ; Liu JH; Fan FS; Yen CC; Lin TC; Jiang JK; Yang SH; Chen PM
    Hepatogastroenterology; 2000; 47(36):1599-603. PubMed ID: 11149011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
    Caudry M; Bonnel C; Floquet A; Marsault C; Quétin P; Pujol J; Maton O; Dujols JP; Caudry Y; Skawinski P
    Am J Clin Oncol; 1995 Apr; 18(2):118-25. PubMed ID: 7900703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: a prospective randomised trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Glimelius B; Jakobsen A; Graf W; Berglund A; Gadeberg C; Hansen P; Kjaer M; Brunsgaard N; Sandberg E; Lindberg B; Sellström H; Lorentz T; Påhlman L; Gustavsson B
    Eur J Cancer; 1998 Apr; 34(5):674-8. PubMed ID: 9713273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial).
    Duffour J; Bouché O; Rougier P; Milan C; Bedenne L; Seitz JF; Buecher B; Legoux JL; Ducreux M; Vetter D; Raoul JL; François E; Ychou M
    Anticancer Res; 2006; 26(5B):3877-83. PubMed ID: 17094417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA drug approval summaries: oxaliplatin.
    Ibrahim A; Hirschfeld S; Cohen MH; Griebel DJ; Williams GA; Pazdur R
    Oncologist; 2004; 9(1):8-12. PubMed ID: 14755010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.